Table of contents

Primary ovarian insufficiency


Key sources

The following summarized guidelines for the evaluation and management of primary ovarian insufficiency are prepared by our editorial team based on guidelines from the American College of Obstetricians and Gynecologists (ACOG 2017), the European Society of Human Reproduction and Embryology (ESHRE 2016), and the Endocrine Society (ES 2015). ...
Show more

Screening and diagnosis

Definition: as per ACOG 2017 guidelines, recognize that POI is a pathologic condition and not a hastening of natural menopause.
Create free account

More topics in this section

  • Diagnostic criteria

  • Indications for testing (symptomatic patients)

  • Indications for testing (family relatives)

Classification and risk stratification

Health risks: as per ACOG 2017 guidelines, ensure a distinct approach to health maintenance in patients with POI from that used in natural menopause, although these two conditions share common health risks.

Diagnostic investigations

Medical history: as per ESHRE 2016 guidelines, elicit symptoms of estrogen deficiency in patients presenting with oligomenorrhea or amenorrhea.

More topics in this section

  • Karyotyping

  • Genetic testing

  • Screening for adrenocortical antibodies

  • Screening for thyroid antibodies

  • Screening for diabetes

  • Screening for infection

  • Cardiovascular evaluation

  • Bone mineral density testing

Medical management

Hormone therapy: as per ACOG 2017 guidelines, initiate systemic hormone therapy, if not contraindicated, to treat hypoestrogenism symptoms and mitigate long-term health risks in patients with POI.
Show 3 more

More topics in this section

  • Duration of treatment

  • Contraception

Patient education

Pre-pregnancy counseling
As per ESHRE 2016 guidelines:
Assess BP, renal function, and thyroid function before pregnancy in patients with premature ovarian insufficiency.
Reassure patients that spontaneous pregnancies after idiopathic premature ovarian insufficiency or most forms of chemotherapy do not show any higher obstetric or neonatal risk than in the general population.